Corvus Pharmaceuticals (CRVS) Scheduled to Post Earnings on Tuesday

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) is scheduled to announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.05. During the same period last year, the firm posted ($0.14) EPS. On average, analysts expect Corvus Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Corvus Pharmaceuticals Stock Down 4.9 %

Shares of CRVS traded down $0.45 during mid-day trading on Wednesday, hitting $8.78. The company had a trading volume of 1,634,069 shares, compared to its average volume of 345,588. Corvus Pharmaceuticals has a 1-year low of $1.23 and a 1-year high of $9.70. The business's 50-day simple moving average is $6.08 and its 200-day simple moving average is $3.67. The stock has a market cap of $549.20 million, a PE ratio of -20.91 and a beta of 1.05.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Mizuho upgraded Corvus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, October 22nd. StockNews.com downgraded Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH boosted their target price on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, September 16th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $10.83.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.